Table 2.
Perioperative outcomes.
| Variable | Value |
|---|---|
| Number of PIPAC | 45 |
| Number of patients per PIPAC cycle | |
| I PIPAC | 20 |
| II PIPAC | 11 |
| III PIPAC | 7 |
| IV PIPAC or more | 4 |
| Access failures | 0/45 (0%) |
| Operative time, min | 95 (71–137) |
| Intraoperative complications | 1*/45 (2%) |
| Overall postoperative morbidity/mortality (CTCAE version 4.0) | |
| Grade 1–2 | 18/45 (40%) |
| Grade ⩾ 3 | 0/45 (0%) |
| Post-operative stay, days ±SD | 2 ± 0.7 |
| Histological tumor response, PRGS | 10/20 (50%) |
| Oxaliplatin | 5/12 (42%) |
| Cisplatin + doxorubicin | 5/8 (62%) |
Values are presented as median (range) or number (%).
*
Small bowel perforation.
CTCAE, Common Terminology Criteria for Adverse Events version 4.0; PIPAC, pressurized intraperitoneal aerosol chemotherapy; PRGS, Peritoneal Regression Grading Score.